ACM
REGN icon

Ascendant Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Ascendant Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-500
Closed -$361K – 77
2022
Q4 		$361K Buy
+500
New +$369K 1.08% 36

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Ascendant Capital Management's REGN Position: Q1 2023 in Review

Ascendant Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2023, closing a stake of 500 shares — an estimated $361K sold.

Ascendant Capital Management first reported a position in REGN in Q4 2022 and held it in 1 quarter. The position peaked at $361K in Q4 2022. 1,192 funds tracked by Wall St. Rank hold REGN as of Q1 2023.

  • Ascendant Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Ascendant Capital Management sold 500 Regeneron Pharmaceuticals shares in Q1 2023, an estimated $361K.
  • Ascendant Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Ascendant Capital Management's Regeneron Pharmaceuticals position peaked at $361K in Q4 2022.
  • 1,192 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2023.

Based on Ascendant Capital Management's 13F filing for Q1 2023, filed 15 May 2023.